niacinamide and pki 587

niacinamide has been researched along with pki 587 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J1
Angulo, P; Chen, C; Cohen, DA; Daily, MF; Evers, BM; Galuppo, R; Gedaly, R; Hundley, J; Musgrave, Y; Shah, M; Spear, BT1
Borg, Å; Cordero, E; Haraldsson, K; Hemann, MT; Kabir, NN; Kazi, JU; Levander, F; Lindblad, O; Macaulay, L; Pietras, K; Puissant, A; Ramos, A; Rönnstrand, L; Stegmaier, K; Sun, J; Vallon-Christersson, J1

Other Studies

3 other study(ies) available for niacinamide and pki 587

ArticleYear
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    The Journal of surgical research, 2012, Volume: 176, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Drug Synergism; Feedback, Physiological; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Triazines

2012
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    The Journal of surgical research, 2013, Volume: 185, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Signaling System; Morpholines; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines

2013
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Oncogene, 2016, 09-29, Volume: 35, Issue:39

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Morpholines; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays

2016